<DOC>
	<DOCNO>NCT01515553</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial test bioequivalence phase 3a formulation liraglutide ( formulation 4 ) liraglutide formulation plan phase 3b trial ( final formulation 4 ) .</brief_summary>
	<brief_title>Bioequivalence Two Liraglutide Formulations Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Good general health judge investigator , base medical history , physical examination include 12lead ECG ( electrocardiogram ) , vital sign blood urinary laboratory assessment BMI ( Body Mass Index ) 18.027.0 kg/m^2 , inclusive History clinically significant renal , hepatic , cardiovascular , pulmonary , gastrointestinal , metabolic , endocrine , haematological , neurological , psychiatric disease major disorder may interfere objective trial , judge Investigator Impaired renal function Any clinically significant abnormal ECG , judge Investigator Active hepatitis B and/or active hepatitis C Positive human immunodeficiency virus ( HIV ) antibodies Known suspect allergy trial product ( ) relate product Pregnant , breastfeed intention become pregnant use adequate contraceptive measure History alcoholism drug abuse , positive result alcohol drug screen Smoking 5 cigarette per day , equivalent tobacco product Habitual excessive consumption methylxanthinecontaining ( theophylline , caffeine theobromine ) beverages food ( coffee , tea , soft drink red bull , cola , chocolate ) judge Investigator Excessive consumption diet deviate normal diet judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>